Your browser does not support iframes.
We intend to do this by increasing access to vital medicines through affordability, innovation and improved treatment outcomes. Through discovery and development of novel biopharmaceuticals, we are working to build a balanced portfolio of innovative Biologics, Biobetters and Biosimilars that is aligned to our core therapeutic areas of expertise.
We have a track record of success in the biologics arena in the US and Europe and we plan to continue building on that success by turning key insights into novel and highly differentiated therapies.
Our biologics pipeline includes multiple product candidates in various stages of development including both novel monoclonal antibody therapeutics and albumin fusion technology-based programs.
Using proprietary novel technologies and validated targets, we are developing new drug candidates that align with key therapeutic areas. Our biologics discovery group is also working on platforms and technologies that are designed to enhance the specificity and delivery of treatment in a way that will maximize their effect.
Our R&D group also spearheads the development of next-generation peptide and protein based therapeutics across a variety of therapeutic categories. Our aims are improved efficacy, reduced dosing frequency and enhanced patient safety and convenience. Through the use of advanced technology platforms, we can improve and expand the use of established biopharmaceuticals as we meet the challenge of optimizing complex manufacturing processes.
Over 35 years ago, Teva became a pioneer in the evolution of the generic medicines movement. Today, our commitment to making innovative medicines more accessible continues, with biosimilars being a logical next step. Teva continues to explore opportunities to include biosimilars and continue our heritage of offering value-based medications.